Clinical Trial Update: Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing immunogenicity and safety of a 15-valent pneumococcal conjugate vaccine in healthy 2- to 3-month-old infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease
• Pneumonia

Drugs mentioned

• 15-valent pneumococcal conjugate vaccine

Snippet

Sponsor: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Conditions: Pneumonia, Pneumococcal | Phase 3 | Status: UNKNOWN